{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:53:27Z","timestamp":1794351207649,"version":"4.9.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":2689,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1038\/modpathol.2015.74","type":"journal-article","created":{"date-parts":[[2015,7,24]],"date-time":"2015-07-24T07:40:50Z","timestamp":1437723650000},"page":"1185-1201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":273,"title":["Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group"],"prefix":"10.1016","volume":"28","author":[{"given":"Elena","family":"Provenzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Badve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"MacGrogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Boughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Michael","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Fastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Kuehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentia","family":"Peintinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-5631","authenticated-orcid":false,"given":"Julia","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2015.74_bib1","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1001\/jama.2011.1837","article-title":"Accelerating identification and regulatory approval of investigational cancer drugs","volume":"306","author":"Esserman","year":"2011","journal-title":"JAMA"},{"key":"10.1038\/modpathol.2015.74_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2015.74_bib3","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27","volume":"30","author":"Mamounas","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.breast.2005.08.002","article-title":"How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?","volume":"15","author":"Apple","year":"2006","journal-title":"Breast"},{"key":"10.1038\/modpathol.2015.74_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2325\/jbcs.13.38","article-title":"Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer","volume":"13","author":"Kuroi","year":"2006","journal-title":"Breast Cancer"},{"key":"10.1038\/modpathol.2015.74_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jncimonographs\/lgr025","article-title":"The pathologic complete response open question in primary therapy","volume":"2011","author":"Marchio","year":"2011","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1038\/modpathol.2015.74_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2559.2006.02419.x","article-title":"Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy","volume":"50","author":"Pinder","year":"2007","journal-title":"Histopathology"},{"key":"10.1038\/modpathol.2015.74_bib8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5858\/133.4.633","article-title":"Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting","volume":"133","author":"Sahoo","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/modpathol.2015.74_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/1874375700903020058","article-title":"Evaluation and reporting of breast cancer after neoadjuvant chemotherapy","volume":"3","author":"Fan","year":"2009","journal-title":"Open Pathol J"},{"key":"10.1038\/modpathol.2015.74_bib10","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/PPO.0b013e31816bdea2","article-title":"A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN)","volume":"14","author":"Chollet","year":"2008","journal-title":"Cancer J"},{"key":"10.1038\/modpathol.2015.74_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.bjc.6601258","article-title":"Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?","volume":"89","author":"Chollet","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1038\/modpathol.2015.74_bib13","first-page":"297","article-title":"Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome","volume":"180","author":"Sataloff","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1038\/modpathol.2015.74_bib14","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.humpath.2007.11.019","article-title":"Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer","volume":"39","author":"Penault-Llorca","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.2015.74_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"10.1038\/modpathol.2015.74_bib16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/annonc\/mds493","article-title":"Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients","volume":"24","author":"Romero","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2015.74_bib17","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.5858\/arpa.2012-0290-OA","article-title":"Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application","volume":"137","author":"Corben","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/modpathol.2015.74_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/modpathol.2015.53","article-title":"Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy","volume":"28","author":"Peintinger","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2015.74_bib19","series-title":"Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy [abstract S6-02]","author":"Symmans","year":"2013"},{"key":"10.1038\/modpathol.2015.74_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mdu508","article-title":"Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy","volume":"26","author":"Sheri","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2015.74_bib21","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","article-title":"Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"29","author":"Mittendorf","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib22","unstructured":"Royal College of Pathologists of Australasia (RCPA). Royal College of Pathologists of Australasia Invasive Breast Cancer Structured Reporting Protocol. 2nd edn. Version 2.0. November 2012."},{"key":"10.1038\/modpathol.2015.74_bib23","first-page":"144","article-title":"Belgian guidelines for laboratory handling and pathology reporting of breast carcinoma after neoadjuvant therapy. Belg J","volume":"5","author":"Lambein","year":"2011","journal-title":"Med Oncol"},{"key":"10.1038\/modpathol.2015.74_bib24","unstructured":"Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe (AGO) http:\/\/www.ago-online.de\/de\/fuer-mediziner\/leitlinien\/mamma\/en\/ Accessed 30 October 2014."},{"key":"10.1038\/modpathol.2015.74_bib25","unstructured":"NHS Breast Screening Programme (NHSBSP). Pathology Reporting Of Breast Disease: A Joint Document Incorporating the Third Edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the Second Edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. NHSBSP Publication No 58. NHS Cancer Screening Programmes jointly with The Royal College of Pathologists; 2005."},{"key":"10.1038\/modpathol.2015.74_bib26","unstructured":"Integraal Kankercentrum Nederland. Beoordeling na neoadjuvante chemo- of endocriene therapie http:\/\/www.oncoline.nl\/breastcancer 2012. Accessed 30 October 2014."},{"key":"10.1038\/modpathol.2015.74_bib27","unstructured":"College of American Pathologists. Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of the Breast. June 2012 http:\/\/www.cap.org\/apps\/docs\/committees\/cancer\/cancer_protocols\/2012\/BreastInvasive_12protocol_3100.pdf Accessed 30 October 2014."},{"key":"10.1038\/modpathol.2015.74_bib28","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1200\/JCO.2007.15.1712","article-title":"Recommendations for collection and handling of specimens from Group breast cancer clinical trials","volume":"26","author":"Leyland-Jones","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/bjc.2012.547","article-title":"A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial","volume":"108","author":"Provenzano","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1038\/modpathol.2015.74_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","article-title":"Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate","volume":"16","author":"Chevallier","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib31","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1200\/JCO.2004.02.122","article-title":"Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer","volume":"22","author":"Dieras","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib32","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib33","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1200\/JCO.2006.08.2271","article-title":"Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome","volume":"25","author":"Mazouni","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib34","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. October 2014 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM305501.pdf Accessed 30 October 2014."},{"key":"10.1038\/modpathol.2015.74_bib35","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","article-title":"Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes","volume":"20","author":"Rouzier","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archsurg.1989.01410010027005","article-title":"The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer","volume":"124","author":"McCready","year":"1989","journal-title":"Arch Surg"},{"key":"10.1038\/modpathol.2015.74_bib37","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2002.20.1.17","article-title":"Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation","volume":"20","author":"Buchholz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib39","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","article-title":"Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy","volume":"23","author":"Hennessy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1245\/ASO.2006.03.010","article-title":"Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer atients is prognostic","volume":"13","author":"Klauber-DeMore","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/modpathol.2015.74_bib41","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2015.74_bib42","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1055\/s-2007-1022338","article-title":"[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]","volume":"54","author":"Sinn","year":"1994","journal-title":"Geburtshilfe und Frauenheilkunde"},{"key":"10.1038\/modpathol.2015.74_bib43","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(11)70117-6","article-title":"Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types","volume":"12","author":"Loi","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2015.74_bib44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2015.74_bib45","unstructured":"Residual Cancer Burden calculator and associated documents [Guide for Measuring Cancer Cellularity, Examples of Gross & Microscopic Evaluation, Pathology Protocol for Macroscopic and Microscopic Assessment of RCB] http:\/\/www3.mdanderson.org\/app\/medcalc\/index.cfm?pagename=jsconvert3 Accessed 30 October 2014."},{"key":"10.1038\/modpathol.2015.74_bib46","doi-asserted-by":"crossref","first-page":"361707","DOI":"10.1155\/2012\/361707","article-title":"The value of combined large format histopathology technique to assess the surgically removed breast tissue following neoadjuvant chemotherapy: a single institution study of 40 cases","volume":"2012","author":"Ibarra","year":"2012","journal-title":"Int J Breast Cancer"},{"key":"10.1038\/modpathol.2015.74_bib47","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1046\/j.1365-2559.1999.0833e.x","article-title":"Typing breast cancer following primary chemotherapy","volume":"35","author":"Carder","year":"1999","journal-title":"Histopathology"},{"key":"10.1038\/modpathol.2015.74_bib48","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1634\/theoncologist.2008-0073","article-title":"Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy","volume":"13","author":"Penault-Llorca","year":"2008","journal-title":"Oncologist"},{"key":"10.1038\/modpathol.2015.74_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10549-013-2411-7","article-title":"Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease","volume":"138","author":"Diaz","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/modpathol.2015.74_bib50","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.20134","article-title":"Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response","volume":"100","author":"Rajan","year":"2004","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2015.74_bib51","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"10.1038\/modpathol.2015.74_bib52","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jamcollsurg.2007.10.016","article-title":"Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count","volume":"206","author":"Belanger","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1038\/modpathol.2015.74_bib53","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.amjsurg.2005.08.041","article-title":"Axillary lymph node count is lower after neoadjuvant chemotherapy","volume":"191","author":"Neuman","year":"2006","journal-title":"Am J Surg"},{"key":"10.1038\/modpathol.2015.74_bib54","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1002\/cncr.25207","article-title":"Number of lymph nodes identified at axillary dissection: effect of neoadjuvant chemotherapy and other factors","volume":"116","author":"Boughey","year":"2010","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2015.74_bib55","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.10741","article-title":"Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18","volume":"95","author":"Fisher","year":"2002","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2015.74_bib56","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1245\/ASO.2003.03.081","article-title":"Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome","volume":"10","author":"Newman","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/modpathol.2015.74_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1054\/brst.2000.0219","article-title":"Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer","volume":"10","author":"Donnelly","year":"2001","journal-title":"Breast"},{"key":"10.1038\/modpathol.2015.74_bib58","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1002\/cncr.25822","article-title":"A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes","volume":"117","author":"Feldman","year":"2011","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2015.74_bib59","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2015.74_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-008-0081-7","article-title":"The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer","volume":"116","author":"Jones","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/modpathol.2015.74_bib61","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-12-3628","article-title":"Ki67 measured after neoadjuvant chemotherapy for primary breast cancer","volume":"19","author":"von Minckwitz","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2015.74_bib62","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2015.74_bib63","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jnci\/djt306","article-title":"An International Ki67 Reproducibility Study","volume":"105","author":"Polley","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2015.74_bib64","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2015.74_bib65","doi-asserted-by":"crossref","unstructured":"Earl HM, Chin S, Dunning M et al. Neo-tAnGo science: a translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy [abstract #1015]. J Clin Oncol 2013;31, (Suppl; abstr 1015).","DOI":"10.1200\/jco.2013.31.15_suppl.1015"},{"key":"10.1038\/modpathol.2015.74_bib66","unstructured":"National Cancer Institute. Breast Oncology Local Disease (BOLD) Task Force of the Breast Cancer Steering Committee. NCI BOLD Task Force Common Data Elements (CDEs) http:\/\/www.cancer.gov\/aboutnci\/organization\/ccct\/steering-committees\/breast-cancer\/ Accessed 30 October 2014."},{"key":"10.1038\/modpathol.2015.74_bib67","series-title":"American Joint Committee on Cancer (AJCC) Cancer Staging Manual","author":"Edge","year":"2009"},{"key":"10.1038\/modpathol.2015.74_bib68","series-title":"American Joint Committee on Cancer (AJCC) Cancer Staging Manual","author":"Greene","year":"2002"},{"key":"10.1038\/modpathol.2015.74_bib69","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jnci\/dji206","article-title":"American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome","volume":"97","author":"Carey","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2015.74_bib70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/PAS.0b013e31817fbdb4","article-title":"Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease","volume":"33","author":"Rabban","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2015.74_bib71","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/annonc\/mdm268","article-title":"Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer","volume":"18","author":"Colleoni","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2015.74_bib72","series-title":"WHO Classification of Tumours of the Breast","author":"Lakhani","year":"2012"},{"key":"10.1038\/modpathol.2015.74_bib73","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.24173","article-title":"Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer","volume":"115","author":"Loya","year":"2009","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2015.74_bib74","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1245\/s10434-012-2318-2","article-title":"Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer","volume":"19","author":"Chen","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/modpathol.2015.74_bib75","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.bjc.6605360","article-title":"Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer","volume":"101","author":"Hirata","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1038\/modpathol.2015.74_bib76","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1634\/theoncologist.12-6-636","article-title":"Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy","volume":"12","author":"Tacca","year":"2007","journal-title":"Oncologist"},{"key":"10.1038\/modpathol.2015.74_bib77","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes","volume":"15","author":"Mittendorf","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2015.74_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10549-012-2047-z","article-title":"Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma","volume":"135","author":"Jabbour","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1038\/modpathol.2015.74_bib79","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3109\/07357907.2011.621913","article-title":"The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis","volume":"29","author":"Zhang","year":"2011","journal-title":"Cancer Invest"},{"key":"10.1038\/modpathol.2015.74_bib80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cancergen.2012.12.001","article-title":"Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management","volume":"206","author":"Valent","year":"2013","journal-title":"Cancer Genet"},{"key":"10.1038\/modpathol.2015.74_bib81","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","article-title":"Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer\u2014results from the GeparQuattro study (GBG 40)","volume":"132","author":"von Minckwitz","year":"2012","journal-title":"Breast Cancer Res Treat"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol201574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201574","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222013758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222013758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol201574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:48:09Z","timestamp":1760230089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222013758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0893395222013758"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2015.74","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2015.74","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}